Thermo Fisher Scientific completes acquisition of PeproTech

Increases capabilities serving the high growth cell and gene therapy market

0
26
Thermo Fisher
Thermo Fisher Scientific completes acquisition of PeproTech, a leader in recombinant proteins.

Thermo Fisher Scientific, in serving science, and PeproTech, a developer and manufacturer of recombinant proteins, announced that Thermo Fisher completed its acquisition of PeproTech on 30 December 2021 for a total cash purchase price of approximately $1.85 billion (approximately Rs 13,748 crore).

Based in Cranbury, New Jersey, PeproTech is a privately held provider of bioscience reagents known as recombinant proteins, including cytokines and growth factors. Recombinant proteins are used in the development and manufacturing of cell and gene therapies as well as in broader cell culture applications, especially for use in cellular research models. PeproTech’s recombinant proteins portfolio complements Thermo Fisher’s cell culture media products and will enable Thermo Fisher to provide customers significant benefits through an integrated offering.

“PeproTech will be an excellent strategic fit within our biosciences business and will allow us to even better serve our pharma and biotech customers by adding new capabilities to our existing offering,” said Marc N Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “In combination with our proprietary bioprocessing and cell culture technologies, this complementary transaction positions us to partner with our customers to drive the evolution of the fast-growing market for cell and gene therapies. By leveraging our commercial reach, we will be able to efficiently grow the PeproTech business and generate attractive financial results all while furthering our Mission to enable our customers to make the world healthier, cleaner and safer.”

Casper added, “With more than three decades of experience across a broad range of applications for drug development and therapeutic products, the PeproTech team has built long-standing customer relationships in pharma and biotech and life sciences research. We look forward to welcoming their incredibly talented team to Thermo Fisher.”

Bob Goldman, president and co-founder of PeproTech, commented, “We are pleased to join Thermo Fisher given their team’s outstanding industry leadership and shared commitment to develop innovative therapies that improve patient outcomes. PeproTech’s reputation for unparalleled product consistency and quality directly aligns with that of Thermo Fisher’s, and we look forward to building on our success as part of the world leader in serving science.”

PeproTech will become part of the biosciences business within Thermo Fisher and will be integrated into the Life Sciences Solutions Segment.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here